Group 1 - Barclays raised its price target on CytomX Therapeutics, Inc. (CTMX) to $10 from $8 and maintained an Overweight rating [1] - Piper Sandler increased its price target to $10 from $6.50, maintaining an Overweight rating, following positive Phase I data on varsetatug maseatecan, which showed a 28% overall response rate and a 94% disease control rate [2] - Guggenheim initiated coverage with a Buy rating and a $10 price target, citing "extraordinary" antitumor activity from Varseta-M in heavily pre-treated patients [2] Group 2 - CytomX Therapeutics, Inc. develops conditionally activated biologics targeting the tumor microenvironment, including antibody-drug conjugates and T-cell engagers [3] - The company is expected to provide an update on approximately 100 metastatic colorectal cancer patients across various dose cohorts this quarter [2]